Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884920 | 1.00 | CA14 (0.50) | CA14TSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1876220 | 1.00 | CA14 (0.50) | CA14TSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20393857 | 0.91 | CA14 (0.43) | CA14TSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21738188 | 0.91 | CA14 (0.43) | CA14TSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13645819 | 0.91 | CA14 (0.43) | CA14TSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7776379 | 0.91 | CA14 (0.43) | CA14TSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11664935 | 0.81 | CA14 (0.52) | CA14TSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30493714 | 0.81 | MEN1 (0.44) | CA14TSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5808282 | 0.80 | TSHR (0.46) | CA14TSHRSMN1; SMN2MAPTGAA | |
| SCHEMBL21488518 | 0.80 | GAA (0.39) | CA14TSHRMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | claimed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | claimed |
| US-20250083136-A1 | METHODS AND SYSTEMS FOR MODIFYING SELECTIVITY IN CATALYTIC REACTIONS | U.S. DEPARTMENT OF ENERGY | 2025-03-13 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-114105801-B | Process for preparing Ac-AA-OR | 成都郑源生化科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023181844-A1 | VIRAL INFECTION INHIBITOR, VIRAL INFECTION INHIBITING MEMBER, AND VIRAL INFECTION INHIBITING PAINT | 積水化学工業株式会社 | 2023-09-28 | — | — | WO | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-1993001199-A1 | CHIRAL PHOSPHOLANES VIA CHIRAL 1,4-DIOL CYCLIC SULFATES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-01-21 | — | — | WO | disclosed |
| US-5171892-A | Chiral phospholanes via chiral 1,4-diol cyclic sulfates | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-12-15 | — | — | US | disclosed |
| EP-0498507-A1 | Process for the preparation of enantiomers of alpha-amino acid derivatives by asymmetric hydrogenation | DSM N.V. (NL) | 1992-08-12 | — | — | EP | disclosed |
| US-5053426-A | Enzyme inhibitors | AMERICAN CYANAMID COMPANY (US) | 1991-10-01 | — | — | US | disclosed |
| US-4962357-A | Two-dimensional method for spectral editing of NMR signals produced by metabolites containing coupled spins | CONTINENTAL AIRLINES, INC. | 1990-10-09 | — | — | US | disclosed |
| EP-0349894-A2 | Two dimensional method for spectral editing of NMR signals produced by metabolites containing coupled spins | GENERAL ELECTRIC COMPANY (US) | 1990-01-10 | — | — | EP | disclosed |
| EP-0076917-B1 | PROCESS FOR MAKING N-ACETYL-2,3-DEHYDROAMINOCARBOXYLIC-ACID ESTERS | Degussa Aktiengesellschaft (DE) | 1985-04-17 | — | — | EP | disclosed |
| EP-0076917-A2 | Process for making N-acetyl-2,3-dehydroaminocarboxylic-acid esters | Degussa Aktiengesellschaft (DE) | 1983-04-20 | — | — | EP | disclosed |
| US-RE29843-E | Substituted thiazoles and flavoring processes and products produced thereby | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1978-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250083136-A1 | METHODS AND SYSTEMS FOR MODIFYING SELECTIVITY IN CATALYTIC REACTIONS | HMBS, UNG, MPG | CA14 1283/4885TSHR 2763/4885MEN1 1968/4885 |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ACE, ZC3HAV1, SARS1 | CA14 1443/4885TSHR 3807/4885MEN1 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.